

Review of: "The α7 Nicotinic Acetylcholine Receptor: a Key Molecule in Post-COVID Syndrome?"

Miguel Guzman-Rivero¹

1 Universidad Mayor de San Simón

Potential competing interests: No potential competing interests to declare.

The participation of α 7 nAChRs (α 7 Nicotinic Acetylcholine Receptor) in the development of Post Acute Sequelae of COVID-19 (PASC), according to the authors, based on previous evidence described in other publications and their own, is very interesting as an explanation based on the presence of anti- α 7 antibodies that may or may not be idiopathic in nature, given that fragment 674-685 of the SARAS-CoV-2 S protein has homology with specific α 7 ligands. This same explanation serves as support to propose as a possible therapeutic option for the control of PASC the use of selective α 7 agonists that stimulate α 7 nAChRs signaling. This information, in my opinion, could serve as a basis for carrying out in silico studies and/or proofs of concept in animal molding, which greatly contributes to the development of the understanding of PASC and its therapeutic approach. In this sense, I consider that the manuscript should be published.

Qeios ID: JKZ848 · https://doi.org/10.32388/JKZ848